Luminex

We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, flow cytometry and imaging, genomic and proteomic research, and food safety.

Launch date

1995

Employees

1001-5000 people

Market cap

Enterprise valuation

$1.8b (Public information from Apr 2021)

Austin Texas (HQ)

http://luminexcorp.com

https://twitter.com/luminex https://www.facebook.com/luminexcorp https://www.linkedin.com/company/luminex-corporation

Revenues, earnings & profits over time

EUR	2016	2017	2018	2019	2020	2021	2022
Revenues	-	279m	287m	305m	379m	435m	474m
% growth	-	-	3 %	6 %	24 %	15 %	9 %
EBITDA	-	56.4m	49.1m	15.5m	65.5m	88.2m	87.3m
% EBITDA margin	-	20 %	17 %	5 %	17 %	20 %	18 %
Profit	-	-	16.4m	(2.7m)	13.6m	41.8m	46.4m
% profit margin	-	-	6 %	(1 %)	4 %	10 %	10 %
R&D budget	46.0m	38.0m	41.0m	50.0m	-	-	-
R&D % of revenue	-	14 %	14 %	16 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Small Business Innovation Research (SBIR)	N/A	-
Mar 2020	ASPR	$642k	Grant
Sep 2020	ASPR	$5.4m	Grant
Sep 2020	ASPR	$684k	Grant
Apr 2021	Diasorin	$1.8b Valuation: $1.8b 4.3x EV/LTM Revenues 25.0x EV/LTM EBITDA	Acquisition
Total Funding		$6.7m